Is the Arabin Pessary really useful in preventing preterm birth? A review of literature

Piccioni, Maria Grazia; Negro, Valentina; Vecchio, Roberta Costanza Bruno; Faralli, Ida; Savastano, Giovanna; Gabriela, Paola; Perrone, Giuseppina

doi:10.1016/j.jogoh.2020.101824

Cited by 4 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another comparable therapy, the vaginal progesterone gel Crinone ® , has failed to receive FDA approval because its efficacy in preventing PTB was not significantly greater than a placebo [ 7 ]. Thus, there is opportunity for a pharmaceutical approach to provide an alternative to mechanical interventions such as a cervical cerclage or pessary [ 31 , 32 , 33 ].…”

Section: Impediments To Treat Ptbmentioning

confidence: 99%

Vaginal Nanoformulations for the Management of Preterm Birth

et al. 2022

View full text Add to dashboard Cite

Preterm birth (PTB) is a leading cause of infant morbidity and mortality in the world. In 2020, 1 in 10 infants were born prematurely in the United States. The World Health Organization estimates that a total of 15 million infants are born prematurely every year. Current therapeutic interventions for PTB have had limited replicable success. Recent advancements in the field of nanomedicine have made it possible to utilize the vaginal administration route to effectively and locally deliver drugs to the female reproductive tract. Additionally, studies using murine models have provided important insights about the cervix as a gatekeeper for pregnancy and parturition. With these recent developments, the field of reproductive biology is on the cusp of a paradigm shift in the context of treating PTB. The present review focuses on the complexities associated with treating the condition and novel therapeutics that have produced promising results in preclinical studies.

show abstract

Section: Impediments To Treat Ptbmentioning

confidence: 99%

Vaginal Nanoformulations for the Management of Preterm Birth

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Another comparable therapy, the vaginal progesterone gel Crinone®, has failed to receive FDA approval [6]. Thus, there is opportunity for a pharmaceutical approach to provide an alternative to mechanical interventions such as a cervical cerclage or pessary [30][31][32].…”

Section: Progesterone Reduces Risks Of Preterm Labor and Birthmentioning

confidence: 99%

Vaginal Nanoformulations for the Management of Preterm Birth

Mir¹,

Patel²,

Vartak³

et al. 2022

Preprint

View full text Add to dashboard Cite

Preterm birth is a leading cause of infant morbidity and mortality in the world. In 2020, 1 in 10 infants were born prematurely in the United States. Globally, the World Health Or-ganization estimates 15 million infants are born prematurely. The efficacy of current ther-apeutic interventions for preterm birth have been called into question due to limited repli-cable success. Recent advancements in the field of nanomedicine have made it possible to utilize the vaginal administration route to effectively and locally deliver drugs to the fe-male reproductive tract. Also, studies using murine models have provided important in-sights about the cervix as a gatekeeper for pregnancy and parturition. It seems plausible that the field of reproductive biology is on the cusp of a paradigm shift in the context of treating preterm birth. The present review focuses on the complexities associated with treating the condition and novel therapeutics that have produced promising results in pre-clinical studies.

show abstract